These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9829525)

  • 1. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit.
    Balkovetz DF; Frazier C; Sanders PW
    Nephrol Dial Transplant; 1998 Nov; 13(11):2979-80. PubMed ID: 9829525
    [No Abstract]   [Full Text] [Related]  

  • 2. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 3. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous administration of epoetin in haemodialysis patients.
    De Vos JY; Upsing L
    EDTNA ERCA J; 2003; 29(3):156-9. PubMed ID: 14552092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
    Scigalla P; Messinger D; Wieczorek L
    Contrib Nephrol; 1990; 82():55-64. PubMed ID: 2093527
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.
    Bommer J; Barth HP; Zeier M; Mandelbaum A; Bommer G; Ritz E; Reichel H; Novack R
    Contrib Nephrol; 1991; 88():136-43. PubMed ID: 2040175
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta.
    Ostrvica E; Mesic E; Ostrvica D; Delic J; Delic-Custendil S; Hukic F
    Med Arh; 2010; 64(1):4-6. PubMed ID: 20422814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
    Cuero CJ; Pérez Guardia E; de Rivera C
    Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Starting r-HuEPO in chronic renal failure: when, why, and how?
    Koene RA; Frenken LA
    Nephrol Dial Transplant; 1995; 10 Suppl 2():35-42. PubMed ID: 7644104
    [No Abstract]   [Full Text] [Related]  

  • 15. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The observation of therapy of anemia in chronic renal failure with recombinant human erythropoietin].
    Jiang Y; Liu P; Wang EJ
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):80-2. PubMed ID: 8070295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
    Trakarnvanich T; Thitiarcharkul S
    J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.